Renovaro Biosciences Valuation
| RENB Stock | 0.61 0.09 17.31% |
Renovaro Biosciences is overvalued. Renovaro Biosciences holds a recent Real Value of USD0.54 per share. The prevailing price of the company is USD0.61. Our model determines the value of Renovaro Biosciences from analyzing the company fundamentals such as Shares Outstanding of 158.72 M, return on equity of -0.9, and Number Of Shares Shorted of 3.41 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Renovaro Biosciences' valuation include:
Price Book 0.9875 | Enterprise Value 100.5 M | Enterprise Value Ebitda (7.37) |
Overvalued
Today
Please note that Renovaro Biosciences' price fluctuation is out of control at this time. Calculation of the real value of Renovaro Biosciences is based on 3 months time horizon. Increasing Renovaro Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Renovaro Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Renovaro Stock. However, Renovaro Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.61 | Real 0.54 | Hype 0.61 | Naive 0.67 |
The real value of Renovaro Stock, also known as its intrinsic value, is the underlying worth of Renovaro Biosciences Company, which is reflected in its stock price. It is based on Renovaro Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Renovaro Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Renovaro Biosciences helps investors to forecast how Renovaro stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Renovaro Biosciences more accurately as focusing exclusively on Renovaro Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Renovaro Biosciences' intrinsic value based on its ongoing forecasts of Renovaro Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Renovaro Biosciences' closest peers. If more than one evaluation category is relevant for Renovaro Biosciences we suggest using both methods to arrive at a better estimate.
Renovaro Biosciences Cash |
|
Renovaro Valuation Trend
Comparing Renovaro Biosciences' enterprise value against its market capitalization is a good way to estimate the value of Renovaro Biosciences uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Renovaro Biosciences Total Value Analysis
Renovaro Biosciences is at this time estimated to have valuation of 100.47 M with market capitalization of 96.86 M, debt of 3.79 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Renovaro Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
100.47 M | 96.86 M | 3.79 M |
Renovaro Biosciences Asset Utilization
One of the ways to look at asset utilization of Renovaro is to check how much profit was generated for every dollar of assets it reports. Renovaro Biosciences holds a negative application of assets of -0.15 pct., losing USD0.001546 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Renovaro Biosciences shows how discouraging it operates for each dollar spent on its assets.Renovaro Biosciences Ownership Allocation
Renovaro Biosciences owns a total of 158.72 Million outstanding shares. Renovaro Biosciences has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Renovaro Biosciences Profitability Analysis
Net Loss for the year was (80.65 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Renovaro Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Renovaro Biosciences and how it compares across the competition.
About Renovaro Biosciences Valuation
The stock valuation mechanism determines Renovaro Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Renovaro Biosciences. We calculate exposure to Renovaro Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Renovaro Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -121.9 K | -128 K | |
| Pretax Profit Margin | (46.25) | (48.57) | |
| Operating Profit Margin | (44.63) | (46.86) | |
| Net Loss | (36.52) | (38.34) | |
| Gross Profit Margin | 0.21 | 0.19 |
Renovaro Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 96.2 M |
Renovaro Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Renovaro Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Renovaro we look at many different elements of the entity such as Renovaro's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Renovaro Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Renovaro Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Renovaro Biosciences' worth.Complementary Tools for Renovaro Stock analysis
When running Renovaro Biosciences' price analysis, check to measure Renovaro Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renovaro Biosciences is operating at the current time. Most of Renovaro Biosciences' value examination focuses on studying past and present price action to predict the probability of Renovaro Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renovaro Biosciences' price. Additionally, you may evaluate how the addition of Renovaro Biosciences to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |